sLex和sLea能够与选择素结合，从而参与到细胞黏附和免疫刺激过程，就此可推断表达表达sLex和sLea的肿瘤细胞在转移和免疫避免（Immune avoidance）上会呈现优势。

2023年10月2日 · Sialyl Lewis a (sLe a), also known as cancer antigen 19-9 (CA19-9), is a tumor-associated carbohydrate antigen. The overexpression of sLe a on the surface of a variety of …

Sialyl Lewis A (SLeA) 是一种碳水化合物类型的抗原，可作为肿瘤标志物，在多种肿瘤细胞中表达上调，如宫颈癌、人胰腺癌和结肠癌细胞。 Sialyl Lewis A 参与肿瘤细胞的迁移与黏附。

2015年5月1日 · The sialyl-Lewis A (sLeA) glycan forms the basis of the CA19–9 assay and is the current best biomarker for pancreatic cancer, but because it is not elevated in ∼25% of …

2023年10月2日 · Sialyl Lewis a (sLe a), also known as cancer antigen 19-9 (CA19-9), is a tumor-associated carbohydrate antigen. The overexpression of sLe a on the surface of a variety of …

2022年6月21日 · In this study, we investigated the blood group antigens SLeX, SLeA and LeY in endometrial cancer, a disease with increasing incidence. A high expression of SLeX and SLeA …

sLeA-targeting antibodies derived from sLeA/KLH–immunized patients protect mice from sLeA + tumor challenge. Several human clones of sLeA-specific antibodies have been derived from …

唾液酸路易斯A（sLeA，也称为CA19-9）是一种四糖，在晚期腺癌（包括结肠癌，胃癌和胰腺癌）中选择性表达并高度表达，长期以来一直被视为主动和被动疫苗接种的诱人靶标。

2013年12月1日 · We investigated the role of carbohydrate antigen sialyl-Lewis a (sLea), an E-selectin ligand and epitope of tumor marker CA19.9, in the development of xenografts in nude …

近年来，治疗方法有所改善，但在晚期阶段，治疗选择仍然有限。 据报道，血型抗原Sialyl Lewis X (SLeX)、Sialyl Lewis A (SLeA)和Lewis Y (LeY)的表达与多种肿瘤的预后相关。 关于子宫内膜 …